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Background/aim: High triglyceride (TG) levels are associated with increases in atherosclerotic cardiovascular disease (CVD), hepatic
steatosis, and pancreatitis. Acute pancreatitis is a condition with high mortality. Therapeutic plasma exchange (TPE) in the treatment
of hypertriglyceridemic pancreatitis (HTGP) is a rapid and effective treatment modality. In this study, the results of TPE were evaluated
and the frequency of lipoprotein lipase (LPL) mutation in these patients was determined.
Materials and methods: TPE was performed in 31 patients with HTGP at the Adult Therapeutic Apheresis Center.
Results: A TG level under 500 mg/dL was achieved by applying apheresis at a median of 2 times (IQR 2–2, min 1, max 6) in the 31 cases.
LPL mutation was detected in 8 (25.8%) of the 31 hypertriglyceridemia cases. When TG levels before and after TPE were evaluated,
the mean TG level before TPE was significantly higher (3132 ± 1472 mg/dL) than the mean TG level afterwards (948 ± 465 mg/dL, P <
0.001). This result represented a decrease of 69.7% TG after TPE.
Conclusion: TPE is a safe, fast, and effective treatment modality in experienced centers.
Key words: Hypertriglyceridemia, pancreatitis, apheresis, therapeutic plasma exchange, fresh frozen plasma

1. Introduction
Hypertriglyceridemia (HTG) is a disorder of lipid
metabolism that is caused by increased dietary intake,
excessive synthesis in the liver, impaired metabolism, or
a combination of these effects [1]. Triglycerides (TGs)
are one of the human body’s main energy sources.
However, high TG levels are associated with increases in
atherosclerotic cardiovascular disease (CVD), hepatic
steatosis, and pancreatitis [2].
Following alcohol consumption and cholelithiasis,
HTG is the third most common cause of acute pancreatitis.
Between 1% and 10% of all acute pancreatitis cases and
56% of pancreatitis cases during pregnancy are secondary
to HTG [2,3].
In HTG, TGs are destroyed by pancreatic lipases,
which cause the release of free fatty acids and subsequent
lipotoxicity, leading to chemical pancreatitis [4]. There
is a known positive correlation between HTG levels and
the risk of pancreatitis. When TG levels are >1000 mg/
dL, the risk of acute pancreatitis is 5%; however, the risk is
10%–20% when TG levels are >2000 mg/dL [5,6]. Despite

this fact, there are no standard predefined TG values for
pancreatitis development.
Insulin, heparin, and apheresis are among the 3
treatment methods approved for the treatment of
hypertriglyceridemic pancreatitis (HTGP). The American
Society for Apheresis has reported that aphaeresis in acute
pancreatitis secondary to HTG should be classified as
indication category III [7]. Those treatments classified as
category III have thus far had inadequate assessments, and
therefore, it has been recommended that individualized
apheresis should only be applied in addition to other
therapeutic treatments [7]. According to the 2016
Guideline, therapeutic plasma exchange (TPE) treatment
should be performed every 1–3 days by targeting TG levels
<1000 mg/dL (ideally <500 mg/dL) in acute pancreatitis
secondary to HTG [7].
Like any invasive procedure, TPE has complications
[7–9]. Bleeding, hematoma, or infection may occur with
catheter use. In addition, patients with pneumothorax may
also experience thrombosis, hypocalcemia, hypotension,
and transfusion reactions due to the procedure.
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Furthermore, angiotensin-converting enzyme inhibitors
may cause anaphylaxis, while respiratory distress and
immunosuppression may occur due to transfusionmediated diseases, air embolisms, pulmonary edema, and/
or pulmonary embolisms [8,9].
Lipoprotein lipase (LPL) gene mutation is one the most
common causes of primary HTG. It was aimed herein to
determine the frequency of LPL mutation in a population
with severe HTG.
Acute pancreatitis has a high mortality rate. Quick
treatment approaches can be life-saving. In the current
study, the results of TPE, which is a rapid, effective, and
safe treatment modality in patients with pancreatitis
secondary to HTG, were evaluated, and the frequency of
LPL mutation in these patients was determined.
2. Materials and methods
In this study, the records of 31 hypertriglyceridemic (HTG)
patients who underwent TPE between 2012 and 2018 at
the Adult Therapeutic Apheresis Center of Ege University,
Faculty of Medicine, were evaluated retrospectively.
In accordance with the protocol of the Adult Therapeutic
Apheresis Center, patients with HTGP, patients who were
not able to use antihyperlipidemic drugs due to their side
effects, or inefficient and pregnant patients with HTG
were chosen for TPE. Inclusion criteria were based on the
Ranson criteria and Balthazar score.
Inclusion criteria for TPE were:
· HTG patients with lactic acidosis
· HTG patients with a white blood cell count >16.000/mm3
· HTG patients with a blood glucose level >200 mg/dL
· HTG patients with lactate dehydrogenase >350 IU/L
· HTG patients with aspartate aminotransferase >250 U/L
· HTG patients with multiorgan failure (e.g., renal failure)
· HTG patients with pancreatic necrosis or fluid
collections on computerized tomography
Exclusion criteria for TPE were:
· HTG patients who could not tolerate or approve central
line placement
· HTG patients who were actively septic or
hemodynamically unstable
· HTG patients with hypocalcemia
· HTG patients who were currently using angiotensinconverting enzyme inhibitors
For each patient, the amount of plasma to be removed
via TPE was determined by the physician, according to
the clinical situation. The patient’s plasma volume was
calculated based on nomograms generated via information
about the patient’s sex, height, weight, and hematocrit
level. Fresh frozen plasma was used as a replacement fluid,
each time, in all of the cases, at a volume of 1–1.5 times the
calculated total plasma volume. The blood flow rate was

set between 55 and 70 mL/min. TPE was performed via
central venous access using a Baxter CS 3000 blood cell
separator (Baxter Healthcare, Deerfield, IL, USA). Vital
signs were monitored at the beginning and end of each
procedure, and patients were monitored for adverse events
during the apheresis procedures. Before each apheresis
procedure, written informed consent was obtained from
each patient after the procedural risks were explained in
detail. Each apheresis session lasted for 2.5–3 h. TPE was
administered daily until almost under 500 mg/dL TG was
achieved.
The patient files were evaluated retrospectively. Results
with positive LPL gene mutation were noted. All exon
and exon-intron compounds that encoded the LPL gene
were evaluated by sequencing at the Medical Genetic
Laboratory. The results were screened retrospectively.
For the statistical analysis, the data were recorded using
the SPSS version 20 (IBM Corp., Armonk, NY, USA).
The descriptive statistics in this study were presented as
numbers (N) and percentages (%). Prior to the statistical
analyses, the data were analyzed to determine whether
they were normally distributed. If so, parametric tests
were used, and if not, non-parametric tests were used. The
Wilcoxon test was used to determine whether there was
a significant difference between the first and last medians
in cases where the data from 2 independent groups were
not normally distributed. In cases where the data were
normally distributed, a t-test was used to determine
whether the differences in the averages of these groups
were significant. Statistical significance was accepted as P
< 0.05.
3. Results
Of the 31 patients in the study, 20 (64.5%) were female and
11 (35.5%) were male. The median and interquartile range
(IQR) of their ages was 40 years (30–49). LPL mutation
was detected in 8 (25.8%) of the patients. A TG level under
500 mg/dL was achieved by applying apheresis at a median
of 2 times (IQR 2–2, min 1, max 6). Three patients (9.7%)
experienced complications related to apheresis [catheter
infection in 2 patients (66.7%) and catheter thrombosis
in 1 patient (33.3%)]. The mean body mass index (BMI)
of the patients was 27.0 ± 5.7 kg/m2. All of the patient
data are shown in Table 1. The mean Ranson score upon
hospital admission was 3.
The mean biochemical results of the 31 patients were
as follows: total cholesterol 459 ± 204 mg/dL, TG 3132 ±
1472 mg/dL, HDL cholesterol 34 ± 21 mg/dL, non-HDL
cholesterol 424 ± 187 mg/dL, LDL cholesterol 86 ± 51 mg/
dL, apolipoprotein (apo) A1 116 ± 43 mg/dL, apo B 105 ±
35 mg/dL, lipoprotein (a) 24 ± 27 nmol/L, 25-OH vitamin
D 16 ± 7 ng/mL. These biochemical data are presented in
Table 2.
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Table 1. Patient data (n: 31).
Variables

Findings

Female (n, %)

20 (64.5)

Pregnant (n, %)

5 (25)

Age (years) (median [IQR])

40 (30–49)

Diabetic (n, %)
Genetic mutations (n, %)
Positive LPL mutation
Negative LPL mutation
Number of plasmapheresis sessions (median
[IQR])
Complication (n, %)

20 (64.5)

Hospitalization time (days)

14 ± 6

BMI (N: 18.5–24.9 kg/m )

27.0 ± 5.7

2

8 (25.8)
23 (74.2)
2 (2–2)
3 (9.7)

Table 2. Mean ± SD biochemical data of all of the groups.

Total cholesterol (N < 200 mg/dL)

Mean ± SD data of all
of the groups (n: 31)
459 ± 204

TGs before TPE (N < 150 mg/dL)

3132 ± 1472

HDL cholesterol (N > 60 mg/dL)

34 ± 21

Variables

Non-HDL cholesterol (N < 160 mg/dL) 424 ± 187
LDL cholesterol (N < 130 mg/dL)

86 ± 51

Apo A1 (N: 104–202 mg/dL)

116 ± 43

Apo B (N: 66–133 mg/dL)

105 ± 35

Lipoprotein (a) (N < 75 nmol/L)

24 ± 27

25-OH vitamin D (N: 30–80 ng/mL)

16 ± 7

When TG levels before and after TPE were evaluated,
the mean TG level before TPE was significantly higher
(3132 ± 1472 mg/dL) than the mean TG level after TPE
(948 ± 465 mg/dL, P < 0.001). This result represented a
decrease of 69.7% TG after TPE. TG values before and
after TPE are presented in Table 3.
When the 8 patients (25.8%) with positive LPL mutation
were compared with the 23 (74.2%) patients without
the LPL mutation, there were no significant differences
between them with regards to total cholesterol, TGs, HDL
cholesterol, non-HDL cholesterol, LDL cholesterol, apo
A1, apo B, lipoprotein (a), 25-OH vitamin D, and BMI.
Of the patients with LPL mutations, three (37.5%) were
diabetic, and their mean hemoglobin A1c (HbA1c) was
8.8%. These data are shown in Table 4.
Of the 20 women included in this study, five (25%) were
pregnant. There were no significant differences between
the 5 pregnant and 15 non-pregnant women with regards
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to total cholesterol, TGs, HDL cholesterol, non-HDL
cholesterol, LDL cholesterol, apo A1, apo B, lipoprotein
(a), 25-OH vitamin D, and BMI. Only 1 pregnant patient
had diabetes mellitus, and her HbA1c was 5.4%. These
data are presented in Table 5.
When the data of the male and female patients were
compared, the only significant difference was between
their apo A1 levels (P = 0.012). These data are presented
in Table 6.
Of the 31 patients included in this study, twenty
(64.5%) were diabetic. The mean HbA1c value of the
diabetic patients was 8.9 ± 2.6%. There was no significant
difference in the average TG levels between the diabetic
and non-diabetic patients (P = 0.905). None of the diabetic
patients had ketoacidosis. However, there was a significant
difference between the diabetic and nondiabetic patients
in terms of BMI (P = 0.007). These data are shown in Table
7.
The mean hospital stay of the patients was 14 ± 6 days
(range: 4–29 days). There were no new local pancreatic
complications or mortality observed during the follow-up.
4. Discussion
Insulin and heparin can be used to increase LPL activity
during the acute phase in patients with pancreatitis
secondary to HTG [4]. In order to reinforce treatment,
antilipidemic medication must be administered using
fibrates as a first choice. Nicotinic acid and omega-3 fatty
acid can also be included in the treatment [4]. With patients
that do not respond to treatment with current therapies,
apheresis is among the options to reduce TG levels in the
blood, allowing the application of TPE. TG levels can be
reduced by 50%–80% with TPE [5]. In the current study,
the TG decrease due to TPE was 69.7%. In the subgroups,
TGs were reduced by 71.3% in those with diabetics, 64.5%
in women, 77.2% in men, 67.3% in pregnant women, and
71.2% in those with LPL mutations. It was hypothesized
that there was less of a reduction in TGs in women because
estrogen is known to accelerate TG synthesis.
The decline in TGs due to TPE was acute but transient,
and should be supported by other medical treatments,
even though current data has indicated that TG levels were
unresponsive to other treatments. The ultimate goal in
these patients was to use TPE to lower the TG level below
500 mg/dL. To protect against hypoglycemia during insulin
infusion, nondiabetic individuals were recommended to
undergo simultaneous dextrose infusion and frequent
blood glucose measurements. TPE can be performed every
2–4 weeks, if oral medication is inadequate, following the
regression of the clinical symptoms of pancreatitis [7]. The
use of apheresis in the treatment of HTG was first reported
by Betteridge et al. in 1978 [10]. Aside from case reports on
the use of apheresis for the treatment of HTGP, the largest
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Table 3. TG levels before and after TPE.
Median [IQR] or mean
± SD TG before TPE
All patients (n: 31)

3132 ± 1472

Female patients (n: 20)

2860 ± 1450

Male patients (n: 11)

3626 ± 1446

Diabetic patients (n: 20)

2829 [2051–4361]

Nondiabetic patients (n: 11)

3176 ± 1473

Pregnant patients (n: 5)

2546 [1996–3430]

Nonpregnant female patients (n: 15)

3219 ± 1560

Patients with LPL mutation (n: 8)

2990 ± 1496

Patients without LPL mutation (n: 23)

3181 ± 1494

Median [IQR] or mean Statistical test and
± SD TG after TPE
P-values
t = 8.871
948 ± 465
P < 0.001
t = 6.944
1015 ± 474
P < 0.001
t = 6.356
827 ± 443
P < 0.001
Z = –2.934
813 [675–1110]
P = 0.003
t = 6.941
944 ± 501
P < 0.001
Z = –2.023
832 [478–1536]
P = 0.043
t = 8.080
944 ± 454
P < 0.001
t = 8.253
1044 ± 385
P = 0.010
t = 3.473
915 ± 493
P < 0.001

Table 4. Median and IQR biochemical data of patients with and without LPL mutation.
Variables

Median [IQR] or mean ± SD
data of patients with LPL
mutation before TPE (n: 8)

Total cholesterol (mg/dL)

413 ± 227

TGs (mg/dL)

2990 ± 1496

HDL cholesterol (mg/dL)

29 [16–45]

Non-HDL cholesterol (mg/dL) 356 [199–495]
LDL cholesterol (mg/dL)

50 ± 28

Apo A1 (mg/dL)

104 [87–121]

Apo B (mg/dL)

88 ± 34

Lipoprotein (a) (nmol/L)

9 [7–30]

25-OH vitamin D (ng/mL)

14 [7–20]

BMI (kg/m2)

24.8 ± 4.6

previously published series was with 20 cases by Chen et
al. [11]. The current study of 31 cases was the largest series
with HTGP.
According to the American Association for Apheresis,
therapeutic apheresis for HTGP is categorized as category
III [7]. Apheresis category III includes disorders for

Median [IQR] or mean ± SD
Statistical test
data of patients without LPL
and P-values
mutation before TPE (n: 23)
t = 0.736
475 ± 199
P = 0.468
t = 0.311
3181 ± 1494
P = 0.758
U = 89.000
30 [21–44]
P = 0.892
U = 73.000
404 [274–631]
P = 0.391
t = 2.567
99 ± 52
P = 0.017
U = 74.000
112 [81–134]
P = 0.760
t = 1.761
113 ± 34
P = 0.090
U = 58.500
14 [9–31]
P = 0.271
U = 77.000
15 [11–22]
P = 0.498
t = 1.262
27.8 ± 5.9
P = 0.217

which the optimum role of apheresis therapy has not been
established. Decision making should be individualized.
Thus, although there have been no recommendations for
plasmapheresis in these patients, this information was
based on expert opinions from case reports. There are
many available therapies for significant HTG, including

875

YILDIRIM ŞİMŞİR et al. / Turk J Med Sci
Table 5. Median and IQR biochemical data of the pregnant and nonpregnant patients.
Variables

Median [IQR] data of the pregnant
patients before TPE (n: 5)

Total cholesterol (mg/dL)

325 [265–425]

TGs (mg/dL)

2556 [1995–3430]

HDL cholesterol (mg/dL)

23 [19–41]

Non-HDL cholesterol (mg/dL)

302 [246–385]

LDL cholesterol (mg/dL)

69 [44–87]

Apo A1 (mg/dL)

148 [111–244]

Apo B (mg/dL)

108 [62–155]

Lipoprotein (a) (nmol/L)

9 [7–37]

25-OH vitamin D (ng/mL)

16 [11–21]

BMI (kg/m2)

25.8 [22–31]

Median [IQR] data of the nonStatistical test and
pregnant patients before TPE (n: 15) P-values
U = 28.000
415 [293–537]
P = 0.445
U = 33.000
2828 [1571–3527]
P = 0.735
U = 34.000
31 [21–40]
P = 0.760
U = 27.000
381 [270–506]
P = 0.359
U = 35.000
65 [48–106]
P = 0.827
U = 14.500
116 [99–133]
P = 0.151
U = 28.000
99 [81–134]
P = 1.000
U = 18.000
17 [9–37]
P = 0.287
U = 32.500
14 [10–20]
P = 0.662
U = 29.000
24.9 [19–28]
P = 0.458

Table 6. Median and IQR biochemical data of the female and male patients.
Variables

Median [IQR] or mean ± SD
Median [IQR] or mean ± SD
data of the female patients before data of the male patients before
TPE (n: 20)
TPE (n: 11)

Total cholesterol (mg/dL)

416 ± 176

537 ± 237

TGs (mg/dL)

2860 ± 1450

3626 ± 1446

HDL cholesterol (mg/dL)

30 [22–40]

30 [13–56]

Non-HDL cholesterol (mg/dL) 336 [271–495]

519 [282–691]

LDL cholesterol (mg/dL)

75 ± 42

107 ± 62

Apo A1 (mg/dL)

119 [103–141]

83 [77–110]

Apo B (mg/dL)

107 ± 42

103 ± 19

Lipoprotein (a) (nmol/L)

14 [8–14]

11 [7–18]

25-OH vitamin D (ng/mL)

15 [10–20]

14 [11–23]

BMI (kg/m2)

25.9 ± 6.4

28.9 ± 3.9

diet, oral lipid-lowering agents, IV insulin, heparin, and
TPE [12]. The final choice of therapy for HTGP may be
influenced by the cost, side effects, and availability of
current therapies. Therefore, a controlled trial evaluating
the efficacy of intravenous insulin, heparin, and TPE may
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Statistical test and
P-values
t = 1.626
P = 0.115
t = 1.407
P = 0.170
U = 101.000
P = 0.710
U = 73.000
P = 0.127
t = 1.685
P = 0.103
U = 37.500
P = 0.012
t = –0.278
P = 0.783
U = 72.500
P = 0.399
U = 103.000
P = 0.772
t = 1.410
P = 0.169

helpful for determining the best choice for the treatment
of acute pancreatitis secondary to HTG. Frankova et al.
reported no superiority of either IV insulin or apheresis for
the treatment of severe HTG among patients hospitalized
for pancreatitis [13]. In addition, the study of Soyaltın et al.
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Table 7. Median [IQR] or mean ± SD biochemical data of the diabetic and nondiabetic patients.
Variables

Median [IQR] or mean ± SD
data of the diabetic patients
before TPE (n: 20)

Median [IQR] or mean ± SD
data of the non-diabetic patients
before TPE (n: 11)

Total cholesterol (mg/dL) 475 ± 214

429 ± 191

TGs (mg/dL)

3176 ± 1473

3108 ± 1509

HDL cholesterol (mg/dL) 30 [18–50]

35 [21–44]

Non-HDL cholesterol
(mg/dL)

392 ± 168

442 ± 198

LDL cholesterol (mg/dL) 96 ± 51

68 ± 48

Apo A1 (mg/dL)

99 [79–128]

121 [104–163]

Apo B (mg/dL)

101 [91–112]

92 [75–139]

Lipoprotein (a) (nmol/L) 13 [9–29]

9 [7–46]

25-OH vitamin D (ng/
mL)

14 [11–22]

17 [8–20]

BMI (kg/m2)

28.9 ± 5.7

23.4 ± 3.9

could not determine any benefit to apheresis treatment over
other treatments in terms of hospital stay, mobility, and
mortality [14]. It has been reported that acute pancreatitis
has a mortality of up to 17% if it necrotizes [15]. TPE was
initially used as the first step in the treatment of HTGP
in order to prevent the pancreatitis from necrotizing, as
well as to prevent organ failure. Apheresis may confer an
additional benefit by removing proteases associated with
acute pancreatitis [16].
Since the treatment modality may vary based on
the type of mutation, the mutation responsible for
primary HTG should be investigated after the exclusion
of secondary causes. For example, fish oil supplements
are effective in the treatment of excessive hepatic
lipase production disorders, but are ineffective and
contraindicated in LPL deficiency, due to their potential
to contribute to an increase in chylomicron. Further,
drugs that reduce lipid levels, such as fibrates, are useful
for treating other lipid metabolism disorders, but are

Statistical test and
P-values
t = –0.578
P = 0.555
t = 0.121
P = 0.905
U = 105.500
P = 0.852
t = –0.704
P = 0.487
t = –1.510
P = 0.142
U = 56.500
P = 0.082
U = 90.000
P = 0.869
U = 78.500
P = 0.468
U = 105.500
P = 0.852
t = –2.878
P = 0.007

generally ineffective in cases with LPL deficiency [17].
The most frequently reported causes of primary HTG are
LPL mutation, apo C-II deficiency, lecithin cholesterol
acyl transferase deficiency, apoC-III overexpression,
apoAV deficiency, excessive synthesis of angiopoietin-like
protein 3, cholesterol ester storage disease, and antibody
deficiency against glycosylphosphatidylinositol-anchored
high-density lipoprotein-binding protein 1 [1,4]. In the
current study, 8 of the 31 HTG patients (25.8%) had an
LPL mutation; however, other genetic mutations were not
investigated. This work had some limitations because it
was performed retrospectively; hence, the clinical severity
of pancreatitis could not be reliably reported.
In conclusion, TPE is a safe, fast, and effective method
used in experienced centers [11,16,18]. Based on the
literature and results obtained from the current study,
it was concluded that TPE is an effective alternative
treatment option for patients with HTGP, as it leads to a
fast and reliable reduction in TG levels.
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